Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Average Target Price of $35.75

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $35.75.

A number of research analysts have recently weighed in on the company. Wall Street Zen lowered Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 target price on shares of Odyssey Therapeutics in a report on Thursday, June 18th. HC Wainwright initiated coverage on Odyssey Therapeutics in a research report on Thursday, August 27th. They issued a “buy” rating and a $44.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Weiss Ratings assumed coverage on shares of Odyssey Therapeutics in a research report on Tuesday, August 11th. They set a “sell (d+)” rating for the company.

Odyssey Therapeutics Stock Performance

NASDAQ ODTX opened at $18.08 on Monday. The firm has a fifty day moving average price of $22.77. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $29.05. The firm has a market cap of $868.92 million and a P/E ratio of -2.67.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter. As a group, sell-side analysts predict that Odyssey Therapeutics will post -6.2 earnings per share for the current year.

Institutional Trading of Odyssey Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ODTX. The Manufacturers Life Insurance Company purchased a new position in shares of Odyssey Therapeutics during the second quarter worth $601,000. State Street Corp purchased a new stake in Odyssey Therapeutics in the second quarter valued at $1,477,000. Finally, Citadel Advisors LLC purchased a new stake in Odyssey Therapeutics in the second quarter valued at $4,162,000.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.